Navigation Links
Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
Date:5/8/2008

cluding patients with moderate to severe chronic pain due to osteoarthritis showed that the efficacy and tolerability of ALO-01 was comparable to marketed extended-release morphine sulfate capsules (KADIAN(R) Capsules). Additionally, when ALO-01 was taken as directed, the sequestered naltrexone had no impact on either pain relief or tolerability.

"The undertreatment of chronic pain and the abuse of prescription opioids are both serious health problems that require urgent attention," said Joseph Stauffer, DO, Chief Medical Officer of Alpharma Pharmaceuticals. "As the data suggest, ALO-01 has the potential to address issues of abuse liability while effectively treating patients with chronic pain."

On April 21, Alpharma announced that it withdrew its New Drug Application (NDA) for ALO-01 and plans to resubmit a revised application in approximately two months. While the initial NDA submission qualified for a priority review, certain technical issues around data presentation prevented a complete evaluation by the U.S. Food and Drug Administration (FDA) within the six month time period permissible for a priority review. Alpharma expects to address the submission issues and re-qualify for priority review in its resubmission, and continues to anticipate a first quarter 2009 launch following approval.

Pain is a serious, undertreated public health problem in the United States, with 19 percent of American adults reporting chronic pain and 34 percent reporting recurrent pain.(1A) Opioids provide effective pain management and are especially useful in treating appropriately selected patients with moderate to severe chronic pain who have not responded adequately to other pain management therapies.(2,3A) However, prescription opioid abuse has escalated along with increased legitimate use in pain management.(1B,4A,5) In fact, 70 percent of people who have abused opioids got them from friends and relatives (by stealing, buying, or being given them).(6) Because of
'/>"/>

SOURCE Alpharma Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
2. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
3. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
4. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
7. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
8. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
9. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
10. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
11. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... , Dec. 22, 2014  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, announced today ... dosed in a pharmacokinetic and pharmacodynamic study with ... neuropathic pain. Racemic methadone is a ... pain states and substitution therapy in opioid addiction.  ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... and developing breakthrough treatments for human disease, today announced that ... development financing collaboration with Symphony Icon Holdings LLC and acquired ... rights to LX1031, LX1032, LX1033 and the other drug programs ...
... announces that a new market research report is available in its catalogue: , ... Hepatitis C Therapeutics Market - Taiwan , ... http://www.reportlinker.com/p0236386/Hepatitis-C-Therapeutics-Market---Taiwan.html , , ... research service aims to provide an update on the epidemiology of Hepatitis C, including the ...
Cached Medicine Technology:Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs 2Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs 3Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs 4Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs 5Hepatitis C Therapeutics Market - Taiwan 2Hepatitis C Therapeutics Market - Taiwan 3Hepatitis C Therapeutics Market - Taiwan 4Hepatitis C Therapeutics Market - Taiwan 5
(Date:12/22/2014)... 2014 On December 22, 2014, My ... Gordon Cashwell for an episode to celebrate Christmas. At ... is it so important to you that we all ... “We all should respect who Jesus was. I think ... Christian beliefs. That means that on Jesus’ birthday we ...
(Date:12/22/2014)... 2014 Physicians in China are most ... treatment of non-Hodgkin’s lymphoma (NHL), according to a new ... healthcare consulting firm. MabThera is the only biologic available ... common form of NHL. , According to Kantar Health’s ... incidence of NHL in China has been growing and ...
(Date:12/22/2014)... 2014 Give a loved one the ... of health and vitality. , For a limited time, ... anti-aging formulas in special Holiday Wellness gift packages at ... , Each bottle contains cutting-edge, proven nutritional support for ... as well as we age. , Joint ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 NAPW ... 2014 Professional Woman of the Year. She is recognized ... the largest, most recognized networking organization of professional women ... the National Association of Professional Women is a vibrant ... Local Chapters. , Ms. Kreider is passionate and committed ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2
... By Amanda Gardner HealthDay Reporter , TUESDAY, April ... take calcium supplements to prevent bone deterioration may, in fact, be ... previous studies with similar findings, the new conclusions don,t necessarily mark ... study released online April 19 in the BMJ . ...
... at the University of Pennsylvania School of Medicine are delving ... of chromosomes. Recent work, e-published in Nature Structural & ... telomeres, can be protected by caps made up of specialized ... Telomere caps are like a knot at the end of ...
... major discovery about an enzyme,s structure has opened a window ... have determined the structure of a nuclease that will help ... for cancer research. DNA repair pathways are very important ... tools the cell uses to do those repairs are not ...
... that will test whether heart disease drugs can be used ... class of drugs - known as statins - can prevent ... cent of pregnant women in the UK. The ... research showing that statins, which are prescribed to lower heart ...
... HealthDay Reporter , TUESDAY, April 19 (HealthDay News) -- ... to curb misuse of extended-release and long-acting opioid pain killers ... Risk Evaluation and Mitigation Strategy (REMS) is part of a ... reduce overall prescription drug abuse in the United States. ...
... The European College of Neuropsychopharmacology (ECNP) is pleased ... the 2011 ECNP Neuropsychopharmacology Award in Basic Science ... the brain adenosine system. The ECNP Neuropsychopharmacology Award ... neuropsychopharmacology and closely related disciplines. The award is ...
Cached Medicine News:Health News:Women Taking Calcium Supplements May Risk Heart Health, Researchers Say 2Health News:Women Taking Calcium Supplements May Risk Heart Health, Researchers Say 3Health News:Ends of chromosomes protected by stacked, coiled DNA caps 2Health News:Ends of chromosomes protected by stacked, coiled DNA caps 3Health News:Nature's elegant solution to repairing DNA in cancer, other conditions 2Health News:Heart drugs could cut blood pressure risks in pregnancy 2Health News:FDA Looks to Crack Down on Misuse of Opioid Painkillers 2Health News:Bertil Fredholm wins the 2011 ECNP Neuropsychopharmacology Award in basic science research 2
For the direct colorimetric determination of alkaline phosphatase in human serum....
Auto LDL-Cholesterol, automated analyzer test kits....
For the quantitative determination of uric acid in serum....
For the quantitative determination of uric acid in serum....
Medicine Products: